The M2-muscarinic receptor inhibits the development of streptozotocin-induced neuropathy in mouse urinary bladder.

The Journal of Pharmacology and Experimental Therapeutics
K J PakF J Ehlert

Abstract

We investigate the role of M(2)-muscarinic receptors in maintaining neurogenic bladder contraction during hyperglycemia. Mice were injected with a single dose of streptozotocin (125 mg/kg), and neurogenic contraction of urinary bladder from wild type and M(2)-muscarinic receptor knockout (M(2) KO) mice was measured at 8 to 24 weeks after treatment. In wild-type bladder lacking urothelium, the summation of the cholinergic (64%) and purinergic (56%) components of the electrical-field-stimulated response exceeded 100%, indicating a reserve capacity. Although the cholinergic component was slightly less in the M(2) KO mouse, the total electrical-field-stimulated contraction was the same as wild type. The cholinergic and purinergic components of contraction in wild-type bladder were minimally affected by streptozotocin treatment. In M(2) KO bladder, streptozotocin treatment reduced both the cholinergic (after 8-9 and 20-24 weeks) and purinergic (after 20-24 weeks only) components. The loss of function was approximately 50 to 70%. Similar results were observed in bladder with intact urothelium. M(2) KO bladder was more sensitive to the relaxant effect of isoproterenol compared with wild type, and this difference significantly increase...Continue Reading

References

Apr 1, 1976·Urology·J T Andersen, W E Bradley
Dec 22, 1983·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·J W Black, P Leff
Mar 9, 1999·Life Sciences·A BravermanM Ruggieri
Aug 16, 2000·Proceedings of the National Academy of Sciences of the United States of America·M MatsuiM M Taketo
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·W C de Groat, N Yoshimura
Mar 2, 2002·Clinical Medicine : Journal of the Royal College of Physicians of London·G Burnstock
Apr 18, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Peter W StengelMarlene L Cohen
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Minoru MatsuiFrederick J Ehlert
May 24, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Alan S Braverman, Michael R Ruggieri
Jan 10, 2004·The Journal of Urology·Penelope A LonghurstMartina W Bezuijen
Jul 23, 2004·Physiological Reviews·Karl-Erik Andersson, Anders Arner
Dec 21, 2004·The Journal of Pharmacology and Experimental Therapeutics·Frederick J EhlertMinoru Matsui
Feb 3, 2005·American Journal of Physiology. Renal Physiology·Guiming Liu, Firouz Daneshgari
Apr 7, 2005·Lancet·Roy Freeman
Jun 21, 2006·Nephron. Experimental Nephrology·Gregory H Tesch, David J Nikolic-Paterson
May 15, 2007·Nephrology·Greg H Tesch, Terri J Allen
Jan 29, 2008·Pharmacology & Therapeutics·Martin C Michel, Maurits M Barendrecht
Oct 23, 2009·The Journal of Urology·Firouz DaneshgariSamuel Chacko

❮ Previous
Next ❯

Citations

Apr 3, 2013·Purinergic Signalling·Geoffrey Burnstock, Ivana Novak
Dec 21, 2010·European Urology·Karl-Erik Andersson
Oct 5, 2012·Acta Physiologica·P OchodnickyM C Michel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.